dimanche 20 septembre 2020


Sunovion Announces Collaboration with AMDA – The Society for Post-Acute and Long-Term Care Medicine

Par Rédaction , dans Communiqués , le 15 décembre 2016

Thursday, December 15th 2016 at 1:00pm UTC

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Sunovion
Pharmaceuticals Inc.
(Sunovion) announced today a collaboration with
AMDA – The Society for Post-Acute and Long-Term Care Medicine, the only
medical specialty society representing the community of over 50,000
medical directors, physicians, nurse practitioners, physician assistants
and other practitioners working in various post-acute and long-term care
(PA/LTC) settings. With support from Sunovion, 2,000 health care
providers will receive resources on COPD management developed by the
Society.

“As an organization dedicated to ensuring patients receive the highest
quality, compassionate PA/LTC, we are pleased to collaborate with
Sunovion on the distribution of these resources,” said Christopher
Laxton, CAE, Society Executive Director. “We believe this initiative
will continue to define and improve quality professional development and
evidence-based clinical guidance for the Society’s members and help the
COPD patients for whom they care.”

Through this collaboration, health care professionals will be provided
with educational materials that focus on preventing COPD morbidity and
mortality; implementing best practices in transitions of care to and
from the hospital and PA/LTC settings while recommending the use of
maintenance therapies for stable COPD, including the appropriate use of
long-acting bronchodilators and anti-inflammatory medications, as
appropriate.

“Sunovion’s support for Society resources represents our commitment to
an important community of caregivers and patients in the post-acute and
long-term care settings,” said Denise Strauss, Vice President, Marketing
at Sunovion. “We are proud to contribute to the understanding of
important advances and best practices in treating COPD.”

For more information please visit www.sunovion.com
and www.paltc.org.

About COPD
Chronic obstructive pulmonary disease, also known
as COPD, includes chronic bronchitis and emphysema, and is a progressive
respiratory disease that causes worsening obstruction to airflow in the
lungs over time.I Approximately 15.7 million adults in the
U.S. report that they have been diagnosed with COPD.II It is
estimated that several million more adults have undiagnosed COPD.III
COPD is responsible for over 120,000 deaths per year, making it the
third leading cause of death in the U.S.III COPD develops
slowly and the symptoms often worsen over time, potentially limiting the
ability to perform routine activities.I Symptoms of COPD
include constant coughing, wheezing, shortness of breath, excess
production of mucus in the lungs, the inability to breathe deeply and
the feeling of being unable to breathe.III

About AMDA – The Society for Post-Acute and Long-Term Care Medicine
AMDA
– The Society for Post-Acute and Long-Term Care Medicine is the only
medical specialty society representing the community of over 50,000
medical directors, physicians, nurse practitioners, physician
assistants, and other practitioners working in various post-acute and
long-term care (PA/LTC) settings. The Society’s 5,500 members work in
skilled nursing facilities, long-term care and assisted living
communities, CCRCs, home care, hospice, PACE programs, and other
settings.

The Society has two affiliate organizations. The American Board of
Post-Acute and Long-Term Care Medicine runs a certification program for
medical directors in PA/LTC, credentialing Certified Medical Directors
(CMDs). The AMDA Foundation oversees awards, community outreach,
education, and research with the mission to advance the quality of life
for persons in PA/LTC through inspiring, educating, and recognizing
future and current health care professionals.

About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a
global biopharmaceutical company focused on the innovative application
of science and medicine to help people with serious medical conditions.
Sunovion’s vision is to lead the way to a healthier world. The company’s
spirit of innovation is driven by the conviction that scientific
excellence paired with meaningful advocacy and relevant education can
improve lives. With patients at the center of everything it does,
Sunovion has charted new paths to life-transforming treatments that
reflect ongoing investments in research and development and an
unwavering commitment to support people with psychiatric, neurological,
and respiratory conditions. Sunovion’s track record of discovery,
development and commercialization of important therapies has included
Brovana® (arformoterol tartrate), Latuda®
(lurasidone HCI), and most recently Aptiom® (eslicarbazepine
acetate).

Headquartered in Marlborough, Mass. Sunovion is an indirect, wholly
owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion
Pharmaceuticals Europe Ltd., based in London, England, Sunovion
Pharmaceuticals Canada Inc., based in Mississauga, Ontario, and Sunovion
CNS Development Canada ULC, based in Toronto, Ontario, are wholly-owned
direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional
information can be found on the company’s web sites: www.sunovion.com,
www.sunovion.eu
and www.sunovion.ca.
Connect with Sunovion on Twitter,
LinkedIn,
Facebook
and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon
Pharma is among the top-ten listed pharmaceutical companies in Japan
operating globally in major pharmaceutical markets, including Japan, the
United States, China and the European Union. Sumitomo Dainippon Pharma
aims to create innovative pharmaceutical products in the Psychiatry &
Neurology area and the Oncology area, which have been designated as the
focus therapeutic areas. Sumitomo Dainippon Pharma is based on the
merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about
7,000 employees worldwide. Additional information about Sumitomo
Dainippon Pharma is available through its corporate website at www.ds-pharma.com.

BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.
LATUDA
is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.
APTIOM
is under license from BIAL.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon
Pharma Co., Ltd.
© 2016 Sunovion Pharmaceuticals Inc.

For a copy of this release, visit Sunovion’s web site at www.sunovion.com

References
I National Heart, Lung and Blood
Institute. What Is COPD? Available at http://www.nhlbi.nih.gov/health/health-topics/topics/copd/.
Accessed: March 2, 2016
II MMWR: Morbidity and Mortality
Weekly Report. Employment and Activity Limitations Among Adults with
Chronic Obstructive Pulmonary Disease — United States, 2013. March 27,
2015; 64(11). Available at http://www.cdc.gov/mmwr/
III
National Heart, Lung, and Blood Institute. “What is COPD?” Available at: http://www.nhlbi.nih.gov/health/educational/copd/what-is-copd/index.htm.
Accessed: March 2, 2016

Contacts

Sunovion Pharmaceuticals Inc.
Kristina Coppola, 508-787-4368
Senior
Manager, Corporate Communications
kristina.coppola@sunovion.com

Source: Sunovion Pharmaceuticals Inc.

Étiquettes : , , , , , , , , ,